Manidipino
Manidipino Uses, Dosage, Side Effects, Food Interaction and all others data.
Manidipino (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Manidipino produces vasodilation resulting in lower blood pressure .
| Trade Name | Manidipino |
| Generic | Manidipine |
| Manidipine Other Names | Manidipine, Manidipino |
| Type | |
| Formula | C35H38N4O6 |
| Weight | Average: 610.711 Monoisotopic: 610.27913496 |
| Protein binding | Manidipine is 99% bound to human plasma proteins . |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Manidipino is a dihydropyridine calcium channel blocker used to treat hypertension.
For the treatment of hypertension.
Manidipino is also used to associated treatment for these conditions: Mild to Moderate Hypertension
How Manidipino works
Contraction of vascular smooth muscle is stimulated by Gq coupled receptors which produce calcium release from the sarcoplasmic reticulum. This is followed by opening of voltage dependent calcium channels and an influx of calcium into the cell ultimately producing contraction. Manidipino binds to and dissociates slowly from L- and T-type voltage dependent calcium channels on smooth muscle cells, blocking the entrance of extracellular calcium into the cell and preventing this contraction . This produces vasodilation which decreases blood pressure. Manidipino produces renal vasodilation and an increase in natriuresis. This likely contributes to the antihypertensive effect by reducing blood volume. Manidipino is selective for the vasculature and does not produce significant effects on the heart or central nervous system at clinically relevant dosages.
Toxicity
The most common adverse events reported in clinical trials were ankle oedema (6%), headache (3.8%), palpitation (2.7%), flushing (2.2%), dizziness (1.6%), rash (0.5%) and fatigue (0.5%) .
Elimination Route
The median Tmax is 1.5 h . Administration with food produces an 1.3-1.6-fold increase in Cmax but no change in Tmax. Manidipino does not accumulate significantly with multiple doses.
Half Life
The half life of elimination has been observed to be dose dependent . Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.
Elimination Route
Manidipino is eliminated through extensive metabolism. 63% is eliminated in the feces and 31% in the urine as metabolites .
Innovators Monograph
You find simplified version here Manidipino
